Literature DB >> 9681851

Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.

M Takahashi1, N Asai, T Iwashita, H Murakami, S Ito.   

Abstract

Biological and biochemical effects of multiple endocrine neoplasia type 2A (MEN-2A), type 2B (MEN-2B) and familial medullary thyroid carcinoma (FMTC) mutations on Ret function were investigated by transfection of NIH 3T3 cells. All mutations examined conferred transforming activity on Ret at variable levels. Cysteine mutations detected in MEN-2A and FMTC induced disulphide-linked homodimers of Ret on the cell surface, leading to activation of its intrinsic tyrosine kinase. Of these cysteine-mutated proteins, Ret with a codon 634 mutation had the highest transforming activity. The activity of Ret with a codon 609, 611, 618 or 620 mutation was approximately three- to five-fold lower than that of Ret with a codon 634 mutation. The first four mutations impaired the Ret cell surface expression or its correct maturation, resulting in the low transforming activity. On the other hand, the MEN-2B mutation appeared to activate Ret by an intramolecular mechanism without dimerization. In addition, we investigated the role of tyrosines present in the intracellular domain for the transforming activity of the mutant Ret proteins. As a result, we found that tyrosine 905 is essential for the transforming activity of the MEN-2A-Ret mutant protein whereas tyrosines 864 and 952 are critical for that of the MEN-2B-Ret mutant protein. Moreover, it turned out that tyrosine 1062 regulates the activity of both MEN-2A-Ret and MEN-2B-Ret and represents a binding site for the Shc adaptor protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681851

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  7 in total

1.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

Review 2.  Towards an evidence-based process for the clinical interpretation of copy number variation.

Authors:  E R Riggs; D M Church; K Hanson; V L Horner; E B Kaminsky; R M Kuhn; K E Wain; E S Williams; S Aradhya; H M Kearney; D H Ledbetter; S T South; E C Thorland; C L Martin
Journal:  Clin Genet       Date:  2011-12-13       Impact factor: 4.438

3.  Quantitative phenotyping as an efficient means to estimate C-cell number in a knock-in mouse model of MEN2B.

Authors:  Aaron Cranston; Louise Howard; C Vyvyan Howard
Journal:  Transgenic Res       Date:  2004-08       Impact factor: 2.788

Review 4.  Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships.

Authors:  Austin A Saugstad; Natasha Petry; Catherine Hajek
Journal:  Front Genet       Date:  2022-05-24       Impact factor: 4.772

5.  A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation.

Authors:  Jinhyang Jung; Shinya Uchino; Youngha Lee; Hoyong Park
Journal:  J Korean Med Sci       Date:  2010-01-21       Impact factor: 2.153

Review 6.  Genetic information in the diagnosis and treatment of hypertension.

Authors:  Maciej Tomaszewski; Lukas Zimmerli; Fadi J Charchar; Anna F Dominiczak
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

7.  Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience.

Authors:  Chutintorn Sriphrapradang; Kitjapong Choopun; Atchara Tunteeratum; Thanyachai Sura
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2017-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.